Evidence map›Paper›PMID 41129739›Full record

ArticleMolecular pharmaceutics2025

Machine Learning Analysis of Cytotoxicity Determinants in Nanoparticle-Based Rheumatoid Arthritis Therapies.

Elif Yildirim, Irem Cakir, Nazar Ileri-Ercan

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elif YildirimChemical Engineering Department, Middle East Technical University, 06800 Ankara, Turkiye.
Irem CakirChemical Engineering Department, Middle East Technical University, 06800 Ankara, Turkiye.
Nazar Ileri-ErcanChemical Engineering Department, Middle East Technical University, 06800 Ankara, Turkiye.ORCID 0000-0003-2251-1859

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticle-based therapies have gained attention in recent years as promising treatments for rheumatoid arthritis (RA), due to the potential offered for targeted delivery, controlled drug release, and improved biocompatibility. A deep understanding of the factors that drive cytotoxicity is crucial for safer and more effective nanomedicine formulations. To systematically analyze the determinants of cytotoxicity reported in the literature, we constructed a data set comprising 2,060 instances from 56 publications. Each instance was described by 23 features covering nanoparticle characteristics, cellular environment factors, and assay conditions potentially associated with cytotoxicity. Machine learning (ML) approaches were incorporated to gain deeper insight into key cytotoxicity drivers. We combined Boruta for feature selection, Random Forest (RF) for cytotoxicity prediction and feature importance evaluation, and Association Rule Mining (ARM) for rule-based, hidden pattern discovery. Boruta feature selection results identified the drug and nanoparticle concentration, core-shell material, and cell type as major determinants of cytotoxicity. The RF model demonstrated a strong predictive performance, further confirming the significance of these features. Moreover, ARM revealed high-confidence association rules linking specific conditions, such as high drug concentrations and poly(aspartic acid)-based systems, to cytotoxic outcomes. This structured machine learning framework provides a foundation for optimizing nanoparticle formulations that balance therapeutic efficacy with cellular safety in RA therapy.

Indexed as

Arthritis, RheumatoidMachine LearningNanoparticlesDrug Delivery SystemsHumansNanomedicineMachine LearningNanoparticlesRheumatoid Arthritis

Identifiers

PMID41129739
PMCPMC12587385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.